Today’s Price Action: Today Aquinox Pharmaceuticals Inc Stock Rises

Today's Price Action: Today Aquinox Pharmaceuticals Inc Stock Rises

The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is a huge mover today! About 170,643 shares traded hands. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 50.76% since April 14, 2016 and is uptrending. It has outperformed by 46.08% the S&P500.
The move comes after 7 months positive chart setup for the $377.39 million company. It was reported on Nov, 16 by We have $22.29 PT which if reached, will make NASDAQ:AQXP worth $166.05M more.

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage

Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. Jefferies maintained Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) rating on Tuesday, March 15. Jefferies has “Hold” rating and $9 price target. As per Friday, August 5, the company rating was maintained by Jefferies. The company was initiated on Friday, October 23 by Needham. Leerink Swann initiated the stock with “Outperform” rating in Monday, September 21 report. Guggenheim initiated Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) rating on Tuesday, October 6. Guggenheim has “Buy” rating and $22 price target. The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) earned “Hold” rating by Canaccord Genuity on Friday, September 11.

According to Zacks Investment Research, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.”

More recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: which released: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. Also published the news titled: “Aquinox Pharmaceuticals stock skyrockets 450%” on August 07, 2015.‘s news article titled: “Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results” with publication date: August 04, 2016 was also an interesting one.

AQXP Company Profile

Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment